You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus

Citation Tools

Article menu

Download PDFPDF

Friday 07 October 2022 from 13:00 to 14:10
Po.6 E- poster session 6: management and recommendations, old and new therapies/biologics
PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wincup C, Dunn N, Ruetsch-Chelli C, et al
PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-elm2022.147